

February 10, 2017



DCAT
TOP ↑
Industry
NEWS

***BUSY WEEK?** Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*



Patheon
A HEALTHIER WORLD. DELIVERED.

Executive insights. Delivered.

[Learn more](#)

1. Teva Appoints Interim CEO

Teva Pharmaceutical Industries has appointed Dr. Yitzhak Peterburg as interim president and CEO with Erez Vigodman stepping down as president and CEO. The change in leadership comes as Teva is proceeding with its integration of the \$40.5-billion acquisition of Allergan's generics business, a deal completed in 2016, and as it faces generic competition for its top-selling specialty drug. [Read More](#)

2. Lilly to Cut 200 Global R&D Positions

Eli Lilly and Company plans to reduce its global R&D workforce by 200 positions, less than 3% of its global R&D workforce, and plans to increase investment in other strategic areas across its US research sites. [Read More](#)

3. Sanofi, Regeneron Win Reprieve in Patent-Infringement Battle with Amgen

A US federal appeals court has stayed a permanent injunction for Sanofi's and Regeneron Pharmaceuticals' Praluent (alirocumaba), an anti-cholesterol drug, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, pending the companies' appeal of the injunction. The permanent injunction had been issued in patent-infringement litigation brought by Amgen, which has a competing PCSK9 inhibitor, Repatha (evolocumab). [Read More](#)

4. Strides Shasun to Spin Out API Business in Company Restructure

Strides Shasun, an Indian pharmaceutical company, is restructuring to form a consumer formulations business to be named Strides Pharma and will spin off of its commodity active pharmaceutical ingredient manufacturing business into a new company. [Read More](#)

5. Novartis Withdraws European Application for Biosimilar

Novartis has withdrawn its marketing authorization application with the European Medicines Agency for a biosimilar candidate to Amgen's Neulasta (pegfilgrastim), one of Amgen's top-selling drugs with 2016 sales of \$4.6 billion. [Read More](#)

6. Kyowa Hakko Kirin Establishes Subsidiary to Sell Amgen Biosimilar

Kyowa Hakko Kirin has established a subsidiary for manufacturing and marketing a biosimilar version of Amgen's anemia drug, Nesp (darbepoetin alfa) in Japan. Nesp (Aranesp in the US) is a top-selling drug for Amgen with \$2.09 billion in 2016 sales. Amgen and Kyowa are partnered in the development

of the biosimilar. [Read More](#)

7. [Allergan Completes \\$2.9-Billion Buy of Regenerative Meds Company](#)

Allergan has completed its acquisition of LifeCell Corporation, the regenerative medicines business of Acelyty, a San Antonio, Texas-based wound care and regenerative medicines company, for approximately \$2.9 billion, which includes manufacturing and research and development operations. [Read More](#)

8. [Pfizer's Submission of ADC Accepted by FDA and EMA](#)

The FDA and the European Medicines Agency have accepted Pfizer's application for marketing approval for Mylotarg (gemtuzumab ozogamicin), an antibody drug conjugate (ADC) for treating acute myeloid leukemia. Mylotarg was the first ADC approved by the FDA in 2000, but Pfizer voluntarily withdrew it from the market in 2010. This news is part of *DCAT Value Chain Insights' Pipeline News*. [Read More](#)

9. [Japanese Court Rules in Favor of Lilly's Vitamin-Regimen Patent](#)

The Japan Intellectual Property High Court has ruled in favor of Eli Lilly and Company and has confirmed the Japan Patent Office's decisions that invalidated trials on Lilly's vitamin-regimen patents for Alimta (pemetrexed for injection), an anti-cancer drug, and one of Lilly's top-selling products with \$2.3 billion in 2016 sales. [Read More](#)

10. [FTC Files Civil Action Against Shire Subsidiary For Generic Antibiotic Delay](#)

The US Federal Trade Commission (FTC) has filed a civil action against Shire's subsidiary, Shire ViroPharma, to permanently prohibit the company from filing further petitions for the antibiotic, Vancocin (vancomycin), in what the FTC says is a delaying tactic to keep generics off the market. [Read More](#)

[DCAT Week '17: Pharma Outsourcing: On the Rise or Not?](#)

Are pharmaceutical companies outsourcing more of their development and manufacturing activities, and what can be expected in 2017 and beyond? The DCAT Week '17 education program, [Pharma Outsourcing: The Numbers, Trends and Partnership Strategies](#), examines the latest, including outsourcing levels, capacity utilization, and strategies for supplier differentiation for both drug substances and drug products. [Read More](#)

[About Top Industry News](#)

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599
www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by dcatnews@dcat.org